Conexiant’s news site is now MDSpire News. Learn more
Advertisement
NASPGHAN Position Paper Outlines Therapeutic Drug Monitoring Targets for Pediatric IBD
A NASPGHAN position paper co-authored by Ashish S. Patel, MD, of Phoenix Children’s outlines therapeutic drug monitoring targets for biologics in pediatric IBD. See the infliximab trough targets and when to call a specialist.
Clinical Scorecard: NASPGHAN Position Paper Outlines Therapeutic Drug Monitoring Targets for Pediatric IBD
At a Glance
Category
Detail
Condition
Clinical topic addressed by the source article: NASPGHAN Position Paper Outlines Therapeutic Drug Monitoring Targets for Pediatric IBD
Key Mechanisms
Therapeutic drug monitoring measures biologic blood levels to guide dosing; anti-TNF monitoring also tracks antibodies against the drug.
Target Population
Children with Crohn’s disease or ulcerative colitis receiving biologic therapy; the source notes that children with perianal fistulas may need higher drug levels and those diagnosed before age 6 may clear infliximab faster.
Care Setting
Care setting described in the source article.
Key Highlights
The 2025 NASPGHAN position paper recommends infliximab trough levels above 18 micrograms per milliliter at week 6 and above 7 micrograms per milliliter at week 14.
The paper recommends proactive infliximab monitoring every 6 to 12 months during maintenance.
Children with perianal fistulas may need higher drug levels; children diagnosed before age 6 may clear infliximab faster and need more intensive dosing and close monitoring.
Proactive monitoring checks drug levels before problems appear; reactive monitoring checks levels after a problem develops.
For newer biologics, monitoring focuses on drug levels, with less concern about antibody formation than with anti-TNF therapy.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
A trough level is the lowest drug level, measured just before the next dose.
The position paper recommends proactive infliximab monitoring every 6 to 12 months during maintenance.
Risks
Reactive monitoring may occur too late to make changes that keep a child on the current therapy; a switch may be needed.
Potential signs of active disease include diarrhea, blood in stool, weight loss, abdominal pain, growth failure, joint pain, skin rashes, eye or mouth involvement, and abnormal liver tests.
Patient & Prescribing Data
Children with Crohn’s disease or ulcerative colitis treated with biologics; the source notes fewer medication options for children than for adults with IBD.
Infliximab trough targets are above 18 micrograms per milliliter at week 6 and above 7 micrograms per milliliter at week 14, followed by proactive monitoring every 6 to 12 months during maintenance. Some children may need higher levels, more intensive dosing, or closer monitoring.
Clinical Best Practices
Discuss concerns about active disease in a child receiving a biologic with a pediatric IBD specialist.
Assess for symptoms outside the gut as well as intestinal symptoms.
Phoenix Children’s has promoted four division chiefs from within the health system to lead vital areas including pediatric intensive care, cardiovascular intensive care, nephrology and physical medicine and rehabilitation.